New drug duo aims to shrink hard-to-treat tumors
NCT ID NCT07073534
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two experimental drugs, SHR-1501 and adbelizumab, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors. About 203 adults aged 18 to 75 will take part across multiple centers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH ADVANCED OR METASTATIC MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China